4Zhang LX,Tu DH,He GX, et al. Risk of tuberculosis infection and tuberculosis meningitis after discontinuation of BCG in Beijing[J]. Am J Respir Crit Care Med, 2000,162:1314～1317 被引量：1
5IUAT Commitee on Prophlaxis. Efficacy of various duration of isoniazid prevetive therapy to tuberculosis:five years of follow up in the IUAT trial[M]. Bull WHO, 1982,60:555～64 被引量：1
6Hong Kong Chest Service/Tuberculosis Research Centre, British Medical Research Council. A double-blind placebo-controlled Clinical of three anti tuberculosis chemoprophylaxia regimens in patients with silicosis in Hong Kong[J]. Am Respir Dis, 1992,145:36～41 被引量：1
7Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommen dations Against the Use of Rifampin and Pyrazinamide for Treatment of Letent Tuberculosis Infection-United States 2003[J]. MMWR 2003,52:735～739 被引量：1
8Watkins RE, Brennan R, Plant AT. Tuberculin reactivity and the risk of tuberculosis a review[J]. Int J Tuberc Dis, 2000,4:895～903 被引量：1
9Zhang LX, Tu DH, An YS, et al. The impact of migrants on the epidemiology of tuberclosis in Beijing, China. INT J Tuberc Dis, 2006, 10: 959-962. 被引量：1
7Edwards LB, Acquaviva FA, Livesay VT, et al. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States[J]. Am Rev Respir Dis,1969,99(4 part 2) :1-132. 被引量：1
